FDA accepts Airway’s IND for AT-100 for bronchopulmonary dysplasia treatment in preterm infants
Bronchopulmonary dysplasia treatment : Airway Therapeutics said that the US Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application for developing AT-100 (rhSP-D) as a preventive treatment for bronchopulmonary dysplasia (BPD) in preterm infants. The US biopharma company will begin a phase 1b randomized clinical trial for confirming the feasibility of […]